| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
| ln Vitro |
Ginsenoside Rg1 stimulates human dental pulp cells (hDPCs) to expand and urinate. Significantly (p<0.05) improved was the ability of hDPCs to proliferate in ginsenoside Rg1, particularly in the Ginsenoside Rg1 (5 μM) group. ALP activity, DSPP and DMP1 gene expression, and ginsenoside Rg1 group and combination group all showed increases (p<0.05) when compared to Jordan [3]. In vitro treatment of p-IκBα and p-p65 with ginsenoside Rg1 decreased NF-κB nuclear translocation, increased PPAR-γ expression, and blocked IκBα phosphorylation in lipopolysaccharide (LPS)-stimulated RAW264.7 cells [2].
|
|---|---|
| ln Vivo |
PPAR-γ levels are dramatically decreased in inflamed joints with adjuvant-induced arthritis (AIA), although p-IκBα and p-p65 levels are significantly destabilized. Ginsenoside Rg1 (G-Rg1) and ginsenoside Rg2 (G-Rg2) decreased the escape latency in the last two days when compared with the Alzheimer's disease (AD) model group (p<0.05). Internal processing of ginsenoside Rg1 reduces IκBα phosphorylation. The duration of time the AD model group model spent in the target quadrant during the space exploration test was significantly shorter each week (p<0.01) than that of the conventional satellite model, as was the number of models that correctly crossed the platform's former position. Ginsenoside Rg1 and Rg2 treatment reversed this trend (ginsenoside Rg1, p<0.01; ginsenoside Rg2, p<0.05). AD-renewed mice's cognitive performance can be significantly enhanced by ginsenoside Rg1 and Rg2 treatment. In APP/PS1 mice, the buildup of Aβ1-42 is decreased by ginsenosides Rg1 and Rg2. Ginsenoside Rg1 and Rg2-treated animals showed a progressive improvement in the pathological defects seen in APP/PS1 mice. characteristic nucleoli and light brown, widely distributed Aβ deposits [1].
|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
M1 (20- O -β- D -glucopyranosyl-20( S )- protopanaxadiol ) is a ppd-type monoglucoside ginsenoside metabolized by intestinal bacteria in humans |
| References |
|
| Additional Infomation |
Ginsenoside Rg1 is a ginsenoside found in Panax ginseng and Panax japonicus var. major that is dammarane which is substituted by hydroxy groups at the 3beta, 6alpha, 12beta and 20 pro-S positions, in which the hydroxy groups at positions 6 and 20 have been converted to the corresponding beta-D-glucopyranosides, and in which a double bond has been introduced at the 24-25 position. It has a role as a neuroprotective agent and a pro-angiogenic agent. It is a 12beta-hydroxy steroid, a beta-D-glucoside, a tetracyclic triterpenoid, a ginsenoside and a 3beta-hydroxy-4,4-dimethylsteroid. It derives from a hydride of a dammarane.
Ginsenosides are a class of steroid glycosides, and triterpene saponins, found exclusively in the plant genus Panax (ginseng). Ginsenosides have been the target of research, as they are viewed as the active compounds behind the claims of ginseng's efficacy. Because ginsenosides appear to affect multiple pathways, their effects are complex and difficult to isolate. Rg1 Appears to be most abundant in Panax ginseng (Chinese/Korean Ginseng). It improves spatial learning and increase hippocampal synaptophysin level in mice, plus demonstrates estrogen-like activity. Ginsenoside RG1 has been reported in Panax notoginseng, Panax ginseng, and Panax vietnamensis with data available. See also: American Ginseng (part of); Asian Ginseng (part of); Panax notoginseng root (part of). |
| Molecular Formula |
C42H72O14
|
|---|---|
| Molecular Weight |
801.02
|
| Exact Mass |
800.492
|
| CAS # |
22427-39-0
|
| PubChem CID |
441923
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
898.5±65.0 °C at 760 mmHg
|
| Melting Point |
194～197 ℃
|
| Flash Point |
497.2±34.3 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.602
|
| LogP |
1.66
|
| Hydrogen Bond Donor Count |
10
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
56
|
| Complexity |
1410
|
| Defined Atom Stereocenter Count |
21
|
| SMILES |
CC(=CCC[C@@](C)([C@H]1CC[C@@]2([C@@H]1[C@@H](C[C@H]3[C@]2(C[C@@H]([C@@H]4[C@@]3(CC[C@@H](C4(C)C)O)C)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)C)O)C)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C
|
| InChi Key |
YURJSTAIMNSZAE-HHNZYBFYSA-N
|
| InChi Code |
InChI=1S/C42H72O14/c1-20(2)10-9-13-42(8,56-37-34(52)32(50)30(48)25(19-44)55-37)21-11-15-40(6)28(21)22(45)16-26-39(5)14-12-27(46)38(3,4)35(39)23(17-41(26,40)7)53-36-33(51)31(49)29(47)24(18-43)54-36/h10,21-37,43-52H,9,11-19H2,1-8H3/t21-,22+,23-,24+,25+,26+,27-,28-,29+,30+,31-,32-,33+,34+,35-,36+,37-,39+,40+,41+,42-/m0/s1
|
| Chemical Name |
(2R,3R,4S,5S,6R)-2-[[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2S)-6-methyl-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-6-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol
|
| Synonyms |
Sanchinoside Rg1; Sanchinoside C1; Ginsenoside RG1
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~124.84 mM)
H2O : ~10 mg/mL (~12.48 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.12 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.12 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.12 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 10 mg/mL (12.48 mM) in Saline (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2484 mL | 6.2420 mL | 12.4841 mL | |
| 5 mM | 0.2497 mL | 1.2484 mL | 2.4968 mL | |
| 10 mM | 0.1248 mL | 0.6242 mL | 1.2484 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
